Results 251 to 260 of about 154,404 (310)

Regression Discontinuity Designs in Epidemiology: A Practical Guide. [PDF]

Clin Epidemiol
O'Keeffe AG, Petersen I.
europepmc   +1 more source

Use of lipid-lowering agents (statins) during pregnancy.

, 2003
Akiko Hosokawa, Benjamin Bar‐Oz, Shinya Ito   +2 more
openalex   +1 more source

HMGCR: a malignancy hub - frontiers in cancer diagnosis and therapy. [PDF]

Front Oncol
Yang Y, Liu Y, Zou T, Liu J, Zhou X, Tao R, Liu S.   +6 more
europepmc   +1 more source

2025 Egyptian guidelines for the management of dyslipidemia. [PDF]

Egypt Heart J
Reda A, Taha HS, Badran HM, Khamis H, Kamal S, Elserafy AS, Dawoud MH, Elamragy AA, Bendary A, Shaker MM.   +9 more
europepmc   +1 more source

Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab. [PDF]

Sci Rep
Dalbeni A, Cattazzo F, Vicardi M, Franceschini E, Campani C, Cabibbo G, Vivaldi C, Palloni A, Pressiani T, Iavarone M, Auriemma A, Natola LA, Federico P, Ponziani FR, Svegliati-Baroni G, Stefanini B, Soldà C, Foschi FG, De Lorenzo S, Garajova I, Marra F, Celsa C, Masi G, Brandi G, Rimassa L, Bruccoleri M, Daniele B, Stella L, Ricci M, Sacerdoti D, Tovoli F, ARTE Study Group.   +31 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Statins

Journal of Obstetrics and Gynaecology Canada, 2003
Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors, otherwise known as statins, are the most common class of lipid lowering medications prescribed today. Although this class of medications is contraindicated in pregnant women and those trying to conceive, there are many individuals who would benefit from these medications.
openaire   +3 more sources